Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, the discussions demonstrate a strong consensus about the positive results from the DAPA-HF trial, often citing phrases like 'significant benefits,' 'long-awaited approval,' and describing the drug as a 'game-changer' for heart failure treatment. The tone, use of technical terms, and references to trial outcomes show deep engagement and recognition of the drug's high-impact significance in medical practice.
Most discussions express strong support and agreement with Dapagliflozin's benefits in heart failure, emphasizing its significance in recent clinical trials.
Posts reveal high interest by referencing multiple studies, highlighting the drug's broad implications for clinical practice, regardless of diabetes status.
Many posts delve into detailed trial results, discuss mechanisms, and urge clinicians to consider the findings, indicating deep engagement.
The discussions highlight the transformative potential of Dapagliflozin in treatment protocols, signaling a major impact on heart failure management worldwide.
2019: DAPA-HF. As a secondary outcome, HF was improving, so dapagliflozin was tested in pts with heart failure and ejection fraction ≤ 40%, regardless of diabetes. Result: decreased hospitalization for HF, decreased death. https://t.co/ilmSWY2zYZ 12/20
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/NdcSKe9RK7 vía @YouTube
The year is 2019 Based on the results of pts with T2D, the SGLT2i dapagliflozin is tested for pts with heart failure and reduced ejection fraction, regardless of diabetes. And it works! DAPA-HF https://t.co/8zkrUPt7PA (11/13)
Dapagliflozin in HFrEF via @readatidbit https://t.co/mAu3b2yd53 Search "Dapagliflozin HFrEF" to find and bookmark this image on GrepMed -> https://t.co/l2BkvuP5sl #foamed #meded #cardiotwitter https://t.co/7pqXOseLM5
心不全に「ダパグリフロジン」を使ったら入院・死亡が減って、脱水・低血糖・腎障害も増えなかったで～というDAPA-HF試験。 ･･･RALES試験の轍を踏まないためには何に気をつけないといけないか、というお話。 N Engl J Med . 2019 Nov 21;381(21):1995-2008. https://t.co/NIlXBPtJ0W
The DAPA HF trial demonstrated the benefit of the SGLT2 inhibitor dapagliflozin in patients with HFrEF, regardless of DM status [@NEJM 2019] See more: https://t.co/bAJjRa6hwb Original article: https://t.co/9crcifkHEr #MedEd #MedTwitter #Medstudenttwitter #CardioTwitter #EBM https://t.co/bAA3zdI99j
Ryker Black reveals findings from a double-blind trial that identifies a revolutionary anti-aging pill, influencing aging processes significantly. The study highlights empagliflozin's positive impact on cardiovascular…
Learn about the optimal medication prescriptions for patients with HFrEF based on the 2021 ESC Guidelines. This video discusses vericiguat, a promising new medication shown to reduce cardiovascular events in high-risk…
This video explores the optimal medication strategies for patients with heart failure and reduced ejection fraction, in accordance with the 2021 ESC Guidelines. It examines the efficacy of new treatments, including…
This week, John Mandrola MD discusses the significant findings of a study involving 1,663 patients with severe heart failure. The research shows that spironolactone, when added to standard treatment, can reduce death…
This video shares insights into the latest heart failure management guidelines from the American Heart Association and European Heart Association. It emphasizes evidence-based recommendations for diagnosis and treatment…
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | New England Journal of Medicine https://t.co/yyQYp6SOro
RT @EndoDialogues: 2019: DAPA-HF. Dapagliflozin was tested in heart failure pts with ejection fraction ≤ 40%, regardless of diabetes, af…
2019: DAPA-HF. Dapagliflozin was tested in heart failure pts with ejection fraction ≤ 40%, regardless of diabetes, after showing potential improvement in HF as a secondary outcome. Result: decreased hospitalization for HF, decreased death. https://t.co/ilmSWYkJd7
@kksft @KobaKobauro @muscle_penguin_ https://t.co/D7owb783N8 ケトン体を増加させる薬剤が心疾患を抑制しているというのが今現在の知見です。
RT @AmbrizMau: En insuficiencia cardíaca con FEVI reducida, el riesgo de empeoramiento de la insuficiencia o muerte cardiovascular es menor…
@stefankmil https://t.co/EMuCjbZJ8M
RT @agingdoc1: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (2019) "Among patients with heart failure and a…
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (2019) "Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than https://t.co/WXf0GPtTyh
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/Sc5Zagtt99
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF – AHA Journals https://t.co/Q5NjoaFyqq
RT @LandmarkTrials: The DAPA HF trial demonstrated the benefit of the SGLT2 inhibitor dapagliflozin in patients with HFrEF, regardless of D…
RT @LandmarkTrials: The DAPA HF trial demonstrated the benefit of the SGLT2 inhibitor dapagliflozin in patients with HFrEF, regardless of D…
RT @LandmarkTrials: The DAPA HF trial demonstrated the benefit of the SGLT2 inhibitor dapagliflozin in patients with HFrEF, regardless of D…
The DAPA HF trial demonstrated the benefit of the SGLT2 inhibitor dapagliflozin in patients with HFrEF, regardless of DM status [@NEJM 2019] See more: https://t.co/bAJjRa6hwb Original article: https://t.co/9crcifkHEr #MedEd #MedTwitter #Medstudenttwitter #CardioTwitter #EBM https://t.co/bAA3zdI99j
@HouseofPain1776 @415GoldIsValue @DrJamesOlsson A. From 2020. B. SGLT2 inhibitors are a repurposed diabetes drug that reduces mortality in patients with HF. https://t.co/L7MCp0eJGc
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF | Circulation Dr Levine quotes this study @ASNKidney #KidneyWk https://t.co/GmbYMwkqSd
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF | Circulation Dr Levine quotes this study @ASNKidney #KidneyWk ...
2019: DAPA-HF. As a secondary outcome, HF was improving, so dapagliflozin was tested in pts with heart failure and ejection fraction ≤ 40%, regardless of diabetes. Result: decreased hospitalization for HF, decreased death. https://t.co/ilmSWY2zYZ 12/20
1) DAPA-HF trial: Among patients with a reduced EF, the risk of worsening heart failure or death from CV causes was lower among those who received dapagliflozin vs placebo. Link: https://t.co/9crcifCQSz https://t.co/sCec6AFpgD
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF | Circulation✅✅✅ https://t.co/0JNpJZ5t0n
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF | Circulation✅✅✅ https://t.co/0JNpJZ5t0n
DAPA-HF 4.744 pacientes com ICFER (FE ≤40% e NYHA ≥ II) randomizados para dapaglifozina 10 mg x placebo Dapagliflozina foi eficaz em reduzir nos pacientes com e sem DM2 o desfecho combinado de mortalidade CV e melhora da IC (menos hospitalização) https://t.co/FaMHuTHUBP
“dapagliflozin had a lower risk of worsening heart failure or death from cardiovascular causes” Dapagliflozin increases LDL
RT @cardiomet_CE: 15) The population enrolled in #EMPEROR_REDUCED when compared to that of #DAPA_HF had higher NYHA III 24% , lower mean #L…
RT @cardiomet_CE: 14) One year later #EMPEROR_REDUCED was published. This trial enrolled >3700 #HFrEF patients irrespective of #TD2M status…
RT @cardiomet_CE: 13b) The pre-specified primary #EP analysis showed that the benefit was significant and with the same magnitude both in d…
RT @cardiomet_CE: 12) Here you can see the characteristics of the enrolled population. 67% of NYHA II, mean #LVEF: 31%, median #NT-proBNP:…
RT @cardiomet_CE: 11) The 1st #RCT published in #HFrEF patients was #DAPA_HF. This trial enrolled >4700 #HFrEF pts irrespective of #T2DM st…
RT @cardiomet_CE: 15) The population enrolled in #EMPEROR_REDUCED when compared to that of #DAPA_HF had higher NYHA III 24% , lower mean #L…
RT @cardiomet_CE: 14) One year later #EMPEROR_REDUCED was published. This trial enrolled >3700 #HFrEF patients irrespective of #TD2M status…
RT @cardiomet_CE: 13b) The pre-specified primary #EP analysis showed that the benefit was significant and with the same magnitude both in d…
RT @cardiomet_CE: 12) Here you can see the characteristics of the enrolled population. 67% of NYHA II, mean #LVEF: 31%, median #NT-proBNP:…
RT @cardiomet_CE: 11) The 1st #RCT published in #HFrEF patients was #DAPA_HF. This trial enrolled >4700 #HFrEF pts irrespective of #T2DM st…
RT @cardiomet_CE: 15) The population enrolled in #EMPEROR_REDUCED when compared to that of #DAPA_HF had higher NYHA III 24% , lower mean #L…
RT @cardiomet_CE: 14) One year later #EMPEROR_REDUCED was published. This trial enrolled >3700 #HFrEF patients irrespective of #TD2M status…
RT @cardiomet_CE: 13b) The pre-specified primary #EP analysis showed that the benefit was significant and with the same magnitude both in d…
RT @cardiomet_CE: 12) Here you can see the characteristics of the enrolled population. 67% of NYHA II, mean #LVEF: 31%, median #NT-proBNP:…
RT @cardiomet_CE: 11) The 1st #RCT published in #HFrEF patients was #DAPA_HF. This trial enrolled >4700 #HFrEF pts irrespective of #T2DM st…
15) The population enrolled in #EMPEROR_REDUCED when compared to that of #DAPA_HF had higher NYHA III 24% , lower mean #LVEF: 27%, and higher #NT_proBNP level: 1900 pg/mL. Previous #HHF 31%, #TDM 50%, mean #eGFR 62 ml/min See
14) One year later #EMPEROR_REDUCED was published. This trial enrolled >3700 #HFrEF patients irrespective of #TD2M status with a similar design of #DAPA_HF. The mean follow-up was shorter than DAPA_HF i.e. 16 months. See
13b) The pre-specified primary #EP analysis showed that the benefit was significant and with the same magnitude both in diabetic vs non-diabetic pts. See
12) Here you can see the characteristics of the enrolled population. 67% of NYHA II, mean #LVEF: 31%, median #NT-proBNP: 1400 pg/mL, Previous #HHF 47%, #TDM 42%, mean #eGFR 65 ml/min. See
11) The 1st #RCT published in #HFrEF patients was #DAPA_HF. This trial enrolled >4700 #HFrEF pts irrespective of #T2DM status (see inclusion criteria). Primary EP was combined #CV_Death, #HHF & #UrgentHFvisit. Mean follow-up has been 18.2 months. See
27a) The first trial to examine #HF as a primary outcome in people w/ & w/o #T2D was the #DAPA_HF study with #Dapagliflozin (
Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HFhttps://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.058910 (2/2)
RT @mbotana: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart F…
RT @FormigaFrancesc: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with…
RT @mbotana: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart F…
RT @moreno_perez_o: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with…
RT @moreno_perez_o: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with…
Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF. | Circulation https://t.co/o2gFYYwfWd
RT @FormigaFrancesc: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with…
RT @FormigaFrancesc: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with…
RT @FormigaFrancesc: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with…
RT @FormigaFrancesc: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with…
RT @FormigaFrancesc: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with…
Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF. https://t.co/GtXFjHJPZ5
RT @FormigaFrancesc: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with…
RT @moreno_perez_o: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with…
RT @moreno_perez_o: Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with…
Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF. @diabeteSEEN @secardiologia @SENefrologia @PepaSolerR @ValleAlfonso https://t.co/QUNsBxmVQx
Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF. https://t.co/1pM58RZVZv @SABOURETCardio @GiuseppeGalati_ @fikkumamoto @paomorejon @JTLLERGO
Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF. https://t.co/cNGbzSWYRH (2/2)
RT @IshiyakuApp: DAPA-HF試験 ・2型糖尿病合併の有無に関わらず、左室駆出率が低下した（LVEF≦40%）心不全に対して、プラセボと比較して、心血管死又は心不全イベント（心不全による入院又は心不全による緊急受診）の発現率の有意な低下を示した https:/…
RT @IshiyakuApp: DAPA-HF試験 ・2型糖尿病合併の有無に関わらず、左室駆出率が低下した（LVEF≦40%）心不全に対して、プラセボと比較して、心血管死又は心不全イベント（心不全による入院又は心不全による緊急受診）の発現率の有意な低下を示した https:/…
DAPA-HF試験 ・2型糖尿病合併の有無に関わらず、左室駆出率が低下した（LVEF≦40%）心不全に対して、プラセボと比較して、心血管死又は心不全イベント（心不全による入院又は心不全による緊急受診）の発現率の有意な低下を示した https://t.co/HijG5UAWWD
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/2xScu8nZFu
According to a new study, #Dapagliflozin in patients with heart failure and reduced ejection fraction-DAPA-HF
EF低下の心不全に治療効果あり‼ フォシーガ（ダパグリフロジン）糖尿病のない心不全にも治療効果あり。 https://t.co/ICJiKQYYaK
RT @mendesthiagob: The year is 2019 Based on the results of pts with T2D, the SGLT2i dapagliflozin is tested for pts with heart failure and…
The year is 2019 Based on the results of pts with T2D, the SGLT2i dapagliflozin is tested for pts with heart failure and reduced ejection fraction, regardless of diabetes. And it works! DAPA-HF https://t.co/8zkrUPt7PA (11/13)
Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction - American College of Cardiology https://t.co/3C1b321EhO
【S22-2】BMIが高い患者、NYHA分類II度、標準治療を受けている患者が多かった。 https://t.co/ZEHogXvDhV #jsphcs2021
@kidney_boy Look at the other non-Nephro studies. That's where I think it shines best (with people who don't even look at kidneys). It seems more beneficial due to overall RAASi or anti-inflammatory affects (to me). https://t.co/EhPg8hS3hf
RT @redGDPS: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/WuFmStudQa
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/WuFmStudQa
#012 Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction N Engl J Med 2019;381:1995-2008.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019.
If it worked for patients with diabetes and HF, what about using it to treat HFrEF regardless of diabetes? It worked! Another landmark study! In 2019 HFrEF treatment gained another ally! https://t.co/8zkrUPt7PA
Abstract Heart Podcast Ep.2 - Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction with Professor Mark Petrie https://t.co/QzUX120CdX
Implementación de Dapagliflozina, usualmente indicado en Diabetes, demuestra éxito al disminuir hospitalizaciones y muertes (por razones cardiovasculares) en pacientes con Insuficiencia Cardiaca https://t.co/7PwMRAluiw
RT @Fizz_DI: 心不全に「ダパグリフロジン」を使ったら入院・死亡が減って、脱水・低血糖・腎障害も増えなかったで～というDAPA-HF試験。 ･･･RALES試験の轍を踏まないためには何に気をつけないといけないか、というお話。 N Engl J Med . 2019…
心不全に「ダパグリフロジン」を使ったら入院・死亡が減って、脱水・低血糖・腎障害も増えなかったで～というDAPA-HF試験。 ･･･RALES試験の轍を踏まないためには何に気をつけないといけないか、というお話。 N Engl J Med . 2019 Nov 21;381(21):1995-2008. https://t.co/NIlXBPtJ0W
Dapagliflozina en pacientes con insuficiencia cardíaca y fracción de eyección reducida https://t.co/UXzfT2bGjc Los tratados con dapagliflozina tuvieron un riesgo menor de empeoramiento de la IC o muerte por causas cardiovasculares que los que recibieron placebo, con y sin DM
RT @vass_vassiliou: @marinrodrigo123 @ldndoc @TharushaGunawa4 @drkeithsiau @drmoutaz @hswapnil @jfdwolff @FadyMFouad Yes, slowly gaining mo…
@marinrodrigo123 @ldndoc @TharushaGunawa4 @drkeithsiau @drmoutaz @hswapnil @jfdwolff @FadyMFouad Yes, slowly gaining momentum in non DM patients with EF<40%. The evidence is there ... and it’s plenty! https://t.co/11FGha8oxP & https://t.co/mjwi9dElMo
RT @AmbrizMau: En INSUFICIENCIA CARDÍACA con FEVI reducida, el riesgo de empeoramiento de la insuficiencia o muerte cardiovascular es MENOR…
https://t.co/SVtyLm2kZG... not a last resort bit after first line therapies have been optimised. ACEi/bb reduce mortality over 2 years by more than 60%... Important to optimise evidence based tx first. https://t.co/fXAaskY1CN
RT @ReenikaVeerasa1: #BeneficialEffectDapagliflozin #Dapgliflozin reduced #WorseningHeartFailure by 3.7% and #CardiovascularDeath by 2.1% i…
Study 1: 'Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction" by J.J. V. McMurray, et al. @NEJM pub. date Nov 21, 2019; https://t.co/CiOm44aS12 DAPA-HF trial bottom line: in pts with HFrEF, regardless of diabetes, dapagliflozin reduced HF and CV death.
Shoqata Mjekësore Shqiptaro- Amerikane do të organizojë seminarin e radhës të Journal Club. Takimi do të fokusohet në menaxhimin e infraktit të zemrës & rishikimit të artikullit "Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction". https://t.co/m7DGBUzvpb https://t.co/S7qPK01Kar
@rainbau_bu @prabhud19 @serioustaurean @MKIttlesonMD https://t.co/Ge2BWsebnG
Because of the results from patients with diabetes, SGLT2i were assessed for use in patients with HFrEF, regardless of diabetes. Again, results were positive, and it is incorporated in cardiovascular care, regardless of diabetes! https://t.co/8zkrUPt7PA
Some worry about the dose of diuretics being given along with #SGLT2i, #McMurray and @scottdsolomon found no change in the diuretic dose among most in FU in #DAPA_HF (similar mean diuretic dose between dapagliflozin/placebo groups) @NEJM @BSHeartFailure DOI: 10.1056/NEJMoa1911303
DAPA-HF: Among heart failure patients regardless of diabetes status, dapagliflozin was associated with lower CV death and hospitalizations for HF #UMKCRCT https://t.co/bJtoyLCHOT
@tolman_susan @NICEComms https://t.co/COymtmPgFm
RT @cpgale3: Read the full @NEJM article here: https://t.co/COymtmPgFm
RT @cpgale3: Read the full @NEJM article here: https://t.co/COymtmPgFm
Read the full @NEJM article here: https://t.co/COymtmPgFm
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
#ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further reading: https://t.co/gZYEfZthJV https://t.co/pxg7VuTPmM https://t.co/TkL1bUZAzh https://t.co/jiReouHd2o https://t.co/afT6tGHSqa https://t.co/0aWpT6gJc6 https://t.co/KSEVGqkcZD
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/KCvZ3h1wSd
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/fzbEicv72a
RT @AAlMohammad87: Mortality of patients with #HFrEF improved with better therapeutics. Based on the placebo arms of #PARADIGM and #DAPA_HF…
RT @AAlMohammad87: Mortality of patients with #HFrEF improved with better therapeutics. Based on the placebo arms of #PARADIGM and #DAPA_HF…
Mortality of patients with #HFrEF improved with better therapeutics. Based on the placebo arms of #PARADIGM and #DAPA_HF, the mortality was 19.8% at 27 months and 13.9% at 18 months, respectively @BSHeartFailure @NEJM DOI: 10.1056/NEJMoa1409077 DOI: 10.1056/NEJMoa1911303
@ValleAlfonso @Dr_Manito @mendez_bailon @ShelleyZieroth @SantasEnrique @JTLLERGO @IcyfaSemi @SABOURETCardio @rafavidalperez @radcliffeCARDIO Same message of improved quality of life was already shown in DAPA-HF (McMurray, NEJM, 2020) and in EMPATROPISM (@SantosGallegoMD JACC 2021) No excuse to not prescribe SGLT2i! https://t.co/PCQeWV4ma9 https://t.co/i0ThLy9OUA
“https://t.co/rFfAKlxKUF” https://t.co/PND7EequSo
RT @Fizz_DI: 「『フォシーガ（ダパグリフロジン）』は10mgで使っても低血糖が少ないから安全」･･･っていうのよく流れてくるのですが、たとえばDAPA-HFの被験者の年齢は66歳くらいと若いですし、低血糖等の兆候があれば減量・中止を行っていたことも押さえておきたいで…
RT @Fizz_DI: 「『フォシーガ（ダパグリフロジン）』は10mgで使っても低血糖が少ないから安全」･･･っていうのよく流れてくるのですが、たとえばDAPA-HFの被験者の年齢は66歳くらいと若いですし、低血糖等の兆候があれば減量・中止を行っていたことも押さえておきたいで…
RT @psukepp: SGLT２。発売当初は、「尿糖排泄促進して糖尿病を良くするなんてなんて邪道な薬なんだ！」と思ってたけど、この心不全に対する効果はすごいね。自分が先見性がなく頭の固い凡々々々々々々々々々々々々々々人であることをまた自覚致しました。 https://t.c…
SGLT２。発売当初は、「尿糖排泄促進して糖尿病を良くするなんてなんて邪道な薬なんだ！」と思ってたけど、この心不全に対する効果はすごいね。自分が先見性がなく頭の固い凡々々々々々々々々々々々々々々人であることをまた自覚致しました。 https://t.co/atYzSWixQ1
#DAPA_HF N Engl J Med 2019; 381:1995-2008 DOI: 10.1056/NEJMoa1911303
RT @rahimkachra: Top 5 papers presented at #RMIM20 by Dr. Tony Battad from @UM_RadyFHS DAPA-HF @NEJM https://t.co/4Xb1rovmf7
Top 5 papers presented at #RMIM20 by Dr. Tony Battad from @UM_RadyFHS DAPA-HF @NEJM https://t.co/4Xb1rovmf7
Dapagliflozin is the first #SGLT2 inhibitor approved by the @US_FDA to reduce the risk of CV death & hospitalizations in patients with #HFrEF, with or without #diabetes. In #DAPA_HF, dapagliflozin significantly reduced the risk of worsening HF or CV death. https://t.co/TDgi3jH9ov https://t.co/6GlIfLq2sp
@drpecarey Peter don't worry you are trading a 26% reduction in MACE [worsening heart failure or death from cardiovascular causes] for a 0.1% chance of DKA whilst DKA isn't great, I'd rather be alive; there was a 17% reduction in total mortality with dapgliflozin https://t.co/uqSx4t7HrP https://t.co/dW2WKKWj7D
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/NdcSKe9RK7 vía @YouTube
RT @Fizz_DI: DAPA-HF study N Engl J Med . 2019 Nov 21;381(21):1995-2008. https://t.co/NIlXBPtJ0W 探索的分析(DM) JAMA . 2020 Mar 27;323(14):1353…
@DrLindaDykes @diet_cokeaddict @atomicallyblond @graeme1spencer @clara_neuro @piugreen DAPA-HF (Nov 2019, https://t.co/0Oy6i8zaqj) and very recently EMPEROR-Reduced (Oct 2020, https://t.co/4PqmVnmYwJ) is the background evidence, for interest
@JohtChandan @KrishnaGokhale @Nirantharakumar @AbdTahrani @anuradhaa_s @TomPMarshall @parthnarendran @ProfNeilThomas @csainsbury @ShamilHaroon @CharlesHallMD Absolute classic: https://t.co/580OQSu6E3 now I rarely have a week where I don’t start someone on one
The correct answer is D. Empagliflozin slows progression of CKD (Creedence Trial) and decreases HF Mort. (Empa-Reg). Weirdly enough Dapagliflozin even decreases HF mortality in those without DM (Dapa-HF)! https://t.co/uQgWHBCtOK https://t.co/OXfmH0xdNX https://t.co/ejiDl9xakh https://t.co/kOM3bZIjde
RT @grepmeded: Dapagliflozin in HFrEF via @readatidbit https://t.co/mAu3b2yd53 Search "Dapagliflozin HFrEF" to find and bookmark this ima…
RT @grepmeded: Dapagliflozin in HFrEF via @readatidbit https://t.co/mAu3b2yd53 Search "Dapagliflozin HFrEF" to find and bookmark this ima…
RT @grepmeded: Dapagliflozin in HFrEF via @readatidbit https://t.co/mAu3b2yd53 Search "Dapagliflozin HFrEF" to find and bookmark this ima…
RT @grepmeded: Dapagliflozin in HFrEF via @readatidbit https://t.co/mAu3b2yd53 Search "Dapagliflozin HFrEF" to find and bookmark this ima…
RT @grepmeded: Dapagliflozin in HFrEF via @readatidbit https://t.co/mAu3b2yd53 Search "Dapagliflozin HFrEF" to find and bookmark this ima…
RT @grepmeded: Dapagliflozin in HFrEF via @readatidbit https://t.co/mAu3b2yd53 Search "Dapagliflozin HFrEF" to find and bookmark this ima…
RT @grepmeded: Dapagliflozin in HFrEF via @readatidbit https://t.co/mAu3b2yd53 Search "Dapagliflozin HFrEF" to find and bookmark this ima…
RT @grepmeded: Dapagliflozin in HFrEF via @readatidbit https://t.co/mAu3b2yd53 Search "Dapagliflozin HFrEF" to find and bookmark this ima…
Dapagliflozin in HFrEF via @readatidbit https://t.co/mAu3b2yd53 Search "Dapagliflozin HFrEF" to find and bookmark this image on GrepMed -> https://t.co/l2BkvuP5sl #foamed #meded #cardiotwitter https://t.co/7pqXOseLM5
https://t.co/SsrBGGwCNB
@DrAMcCullough @mvaduganathan @sameerbansilal @andrewwsteele 0.83 in a pop w eGFR 85, 50% of which was eGFR >90, and two-thirds without ASCVD (Fig 2). DAPA-HF (https://t.co/rxKxRWBcY1) CVD/HHF HR was 0.75 in a pop w avg eGFR 66, w 40% <60 (Table 2). Now DAPA-CKD CVD/HHR HR was 0.71 in a pop w avg eGFR 43 (see my posted thread for data).
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/7wD7VmKHA5
The industry-funded DAPA-HF trial, an RCT of 4744 patients with NYHA class II, III, or IV heart failure and an ejection fraction ≤40% on standard therapy were randomized to dapagliflozin 10mg once daily vs. placebo. https://t.co/yGLCvZtwSs
RT @LeivaOrly: @melanie_fritz_ https://t.co/xfti90YCNC
Today we take a dive into the world of #Cardiology and look at key research findings surrounding dapagliflozin and #heartfailure Check out our infographic at: https://t.co/KD5k5RSD1G #medtwitter #MedEd #medicine #FOAMed https://t.co/5n00oqDG6c
@HashThatMotd https://t.co/0GXveLiqC5 This is a clinical trial. Kalau medical field, this is your black and white saying your evidence. Kalau bagi article just saying “researches have find out etc etc” siapa researchernya, kat mana, siapa samples, methodology, findings etc
@DrBaikin DAPA-HFのことです
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. https://t.co/OEGjKiPUkT
@AmbrizMau Y en pacientes con insuficiencia cardíaca aguda con fevi reducida mejora mortalidad y disminuye hospitalizaciones vs enalapril. En pacientes diabeticos y no diabeticos. NEJM 2019; DOI: 10.1056/NEJMoa1911303
RT @drstak70: #Dapagliflozin Slows #Type2Diabetes Onset in Heart Failure Patients. #DAPA_HF trial #HeartFailure https://t.co/vtpbumYmBC
#Dapagliflozin Slows #Type2Diabetes Onset in Heart Failure Patients. #DAPA_HF trial #HeartFailure https://t.co/vtpbumYmBC
REFs (part 1): [1]https://t.co/13yFRkA2QY [2]https://t.co/V0GVgFxea7 [3]https://t.co/p8geXZRCom [4]https://t.co/nZ6i7FyWgQ [5]https://t.co/5Z9ivg5bvG [6]https://t.co/XPeJTx7IQM [7]https://t.co/lDh3skGs5z [8]https://t.co/bQUTnrQbSB [9]https://t.co/21rdH5qbEo
https://t.co/vinvl0AFRC
RT @arjunamaharaj: Interesting and (relatively) recent trial: DAPA-HF. Currently ACEi, MRA, and BB used first line for HFrEF. DAPA-HF shows…
Interesting and (relatively) recent trial: DAPA-HF. Currently ACEi, MRA, and BB used first line for HFrEF. DAPA-HF shows SGLT-2i reduces CVD death and hospitalization for HF even in non-diabetics: https://t.co/BZASdeUA8q @NEJM https://t.co/LRoYfQkfy9
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @NephJC: useful links for #NephJC Summary: @agrawalkris & @DrFlashHeart https://t.co/lBOMTTCiKG Original article: https://t.co/J0LimkSnj…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @NephJC: useful links for #NephJC Summary: @agrawalkris & @DrFlashHeart https://t.co/lBOMTTCiKG Original article: https://t.co/J0LimkSnj…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
useful links for #NephJC Summary: @agrawalkris & @DrFlashHeart https://t.co/lBOMTTCiKG Original article: https://t.co/J0LimkSnjW We will also touch on DAPA-HF https://t.co/UpTSRpxyUJ #NephMadness 2020 SGLT2i region: https://t.co/3yFsrfJ78O VA by @docanjuyadav and @drM_sudha https://t.co/BeMbyPQPR3
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @NephJC: Other useful links for tonight's #NephJC: Main full text article: https://t.co/J0Liml9YIw We will also touch on DAPA-HF https…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
RT @edgarvlermamd: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects #VisualAbstract by @drM_sudha and @docanjuyadav #Nep…
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/JT1j5grlJ9
In the DAPA-HF trial of heart failure patients with reduced ejection fraction, even though 60% of patients did not have diabetes, SGLT2i were associated with significant decrease in risk of worsening heart failure or cardiovascular death. https://t.co/VBn3rsR0tq
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/GXDIndNACQ
Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction - American College of Cardiology https://t.co/7igly8n5nr
RT @rblument1: Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction - American College of Cardiology https://t.co/NMC…
Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction - American College of Cardiology https://t.co/NMCcFe5Pp6
Trend up+7241: *McMurray JJV* et al (N Engl J Med) __Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply__ https://t.co/ZjuuQH8nuf
Trend new: *McMurray JJV* et al (N Engl J Med) __Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply__ https://t.co/ZjuuQH8nuf
Trend up+8789: *McMurray JJV* et al (N Engl J Med) __Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply__ https://t.co/ZjuuQH8nuf
Trend up+8790: *McMurray JJV* et al (N Engl J Med) __Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply__ https://t.co/ZjuuQH8nuf
Trend new: *McMurray JJV* et al (N Engl J Med) __Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply__ https://t.co/ZjuuQH8nuf
Trend new: *McMurray JJV* et al (N Engl J Med) __Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply__ https://t.co/ZjuuQHpYlN
Trend new: *McMurray JJV* et al (N Engl J Med) __Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply__ https://t.co/ZjuuQH8nuf
Trend new: *McMurray JJV* et al (N Engl J Med) __Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply__ https://t.co/ZjuuQH8nuf
Trend up+5: *McMurray JJV* et al (N Engl J Med) __Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply__ https://t.co/ZjuuQH8nuf
Trend new: *McMurray JJV* et al (N Engl J Med) __Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply__ https://t.co/ZjuuQH8nuf
Trend new: *McMurray JJV* et al (N Engl J Med) __Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Reply__ https://t.co/ZjuuQH8nuf
Be on the look out for CHF patients on SGLT2 inhibitors, not for diabetes, but for heart failure. Dapagliflozin in patients with heart failure and reduced ejection fraction McMurray et al. NEJM 2019
2-Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction - DAPA-HF https://t.co/zx3HbNEWl2
DAPA-HF Trial Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/yvD1jDv6Ik https://t.co/AOSioZOxrL
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/Y2jxQHoL70
RT @SeanShirvaniMD: Honestly, SGLT2 inh. feel like a joke on those who had to prescribe or take sulfonylureas, a drug class that made physi…
Honestly, SGLT2 inh. feel like a joke on those who had to prescribe or take sulfonylureas, a drug class that made physicians and patients choose between gaining weight or controlling their HbA1c. 6/n https://t.co/UtURw4Q6bg
RT @keiryuu_iwana: 今回のJJCLIPお題論文（Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction）とさらっと見た感じ、同時期の似た解析論文にみえるけどどうだろう…
今回のJJCLIPお題論文（Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction）とさらっと見た感じ、同時期の似た解析論文にみえるけどどうだろう？ 結果の違いは何によるものだろう？ https://t.co/mLiGS5dJvO
RT @cristinatejerap: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/zveYeZ3Jwh
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction @NEJM #PildorasGBE @semeg_es https://t.co/CsACvgu8N9
If you're about to give placebo to treat heart failure with reduced ejection fraction think twice. Dapaglifozin could be slightly better. #bias #Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/aIdwXraIfw
RT @landmarkstudies: #Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction #VisualAbstract #HeartFailure #Diabetes #H…
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. https://t.co/QoUlD5doIq
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med #cancer #epidemiology https://t.co/SNR4q4VI49
RT @SCCMPresident: In a phase 3 trial, what is the effect of Dapagliflozin in patients with heart failure and reduced ejection fraction? @S…
RT @SCCMPresident: In a phase 3 trial, what is the effect of Dapagliflozin in patients with heart failure and reduced ejection fraction? @S…
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @cristinatejerap: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/zveYeZ3Jwh
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://t.co/vPi6aFwBgf
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
RT @NEJM: Original Article: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction https://t.co/eijiVIxuon
https://www.nejm.org/doi/full/10.1056/NEJMoa1911303#.XYfnDR5HEWw.twitter
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa1911303#.XYfnDR5HEWw.twitter
RT @SEDiabetes: Estudios #DAPA-HF #DEFINE-HF demuestran el beneficio con iSGLT2 en insuficiencia cardiaca en personas con y sin DM tipo 2 #…
RT @SEDiabetes: Estudios #DAPA-HF #DEFINE-HF demuestran el beneficio con iSGLT2 en insuficiencia cardiaca en personas con y sin DM tipo 2 #…
RT @SEDiabetes: Estudios #DAPA-HF #DEFINE-HF demuestran el beneficio con iSGLT2 en insuficiencia cardiaca en personas con y sin DM tipo 2 #…
Estudios #DAPA-HF #DEFINE-HF demuestran el beneficio con iSGLT2 en insuficiencia cardiaca en personas con y sin DM tipo 2 #EASD2019 https://t.co/NQRPJ0uJYq
T
DB